Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07108283 · ClinicalTrials.gov registry record · Phase 2
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
A Phase 2 study of NonSegmental Vitiligo, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT07108283 is a Phase 2 study of NonSegmental Vitiligo that is actively recruiting participants, run by Takeda. The registered enrollment target is 200 participants, below the 366-participant average among 3 other NonSegmental Vitiligo trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT07108283, a Phase 2 study of NonSegmental Vitiligo, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches). The main aim of this study is to learn how safe zasocitinib is, how well it works and how well it is tolerated by adults with nonsegmental vitiligo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 1 year (52 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. Participants who receive placebo at the beginning will change to zasocitinib after about 6 months. During the study, participants will visit their study clinic 11 times.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Zasocitinib
Study Locations (20)
California
- First OC Dermatology - Fountain Valley
- Center for Dermatology Clinical Research, Inc. - Fremont
- The Vitiligo & Pigmentation Institute of Southern California - Los Angeles
- UC Davis Department of Dermatology - Sacramento
- Therapeutics Clinical Research - San Diego
Florida
- Encore Medical Research of Boynton Beach LLC. - Boynton Beach
- San Marcus Research Clinic, Inc. - Miami Lakes
- Advanced Clinical Research Institute (ACRI) - Tampa
- Encore Medical Research of Weston LLC - Weston
New York
- Mount Sinai - New York
- Weill Cornell Medicine - New York
- Markowitz Medical dba Optiskin - New York
Louisiana
- DelRicht Research - Dermatology - Baton Rouge
- DelRicht Research (Audubon Dermatology) - New Orleans
Arkansas
- Dermatology Trial Associates - Bryant
Maryland
- Lawrence J Green LLC - Rockville
Michigan
- Hamzavi Dermatology - Canton - Canton
Ohio
- Bexley Dermatology (legal entity - Dermatologists of Southwestern Ohio, LLC) - Bexley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2027-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07108283
The ClinicalTrials.gov registry entry for NCT07108283 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 366-participant average among 3 other NonSegmental Vitiligo trials with a reported enrollment target (45% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NonSegmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07108283 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT07108283 about?
NCT07108283 is a clinical study titled "A Study of Zasocitinib in Adults With Nonsegmental Vitiligo". Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less...
What is the current status of trial NCT07108283?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-11-03. Estimated completion is 2027-11-09.
What conditions does trial NCT07108283 study?
This clinical trial studies the following conditions: NonSegmental Vitiligo.
What interventions are being tested in trial NCT07108283?
The interventions under investigation include: Placebo (OTHER), Zasocitinib (DRUG).
Who is sponsoring clinical trial NCT07108283?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07108283 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NonSegmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.